Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704556 | 0.85 | RAB9A (0.56) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3091048 | 0.85 | SLC6A4 (0.51) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3102333 | 0.85 | ALDH1A1 (0.62) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3914366 | 0.85 | NPC1 (0.70) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2665747 | 0.84 | ALDH1A1 (0.61) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4184070 | 0.82 | ALDH1A1 (0.44) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3101093 | 0.81 | CFTR (0.50) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3099900 | 0.80 | SCN10A (0.54) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL12876531 | 0.78 | ALDH1A1 (0.48) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3101392 | 0.76 | HDAC6 (0.52) | RAB9ANPC1ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103230389-A | Novel nitrocatechol derivatives having selectin ligand activity | REVOTAR BIOPHARMACEUTICALS AG | 2013-08-07 | — | — | CN | disclosed |
| US-8461207-B2 | Phloroglucinol derivatives having selectin ligand activity | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8461207-B2 | Phloroglucinol derivatives having selectin ligand activity | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-06-11 | — | — | US | disclosed |
| CN-101374508-B | Novel nitrocatechol derivatives having selectin ligand activity | REVOTAR BIOPHARMACEUTICALS AG | 2013-04-24 | — | — | CN | disclosed |
| EP-1948146-B1 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-11-07 | — | — | EP | disclosed |
| EP-1948146-B1 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-11-07 | — | — | EP | disclosed |
| US-8278356-B2 | — | — | 2012-10-02 | — | — | US | disclosed |
| US-8278356-B2 | — | — | 2012-10-02 | — | — | US | disclosed |
| CN-101267811-B | Novel multi-cyclic compounds and their use | REVOTAR BIOPHARMACEUTICALS AG | 2012-07-25 | — | — | CN | disclosed |
| US-20110152291-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-06-23 | — | — | US | disclosed |
| EP-1948146-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | Revotar Biopharmaceuticals AG (DE) | 2008-07-30 | — | — | EP | disclosed |
| EP-1937238-A1 | NOVEL NITROCATECHOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | Revotar Biopharmaceuticals AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1937237-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | Revotar Biopharmaceuticals AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039114-A1 | NOVEL NITROCATECHOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039114-A1 | NOVEL NITROCATECHOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039112-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039112-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039111-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039111-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1764093-A1 | Novel aromatic compounds and their use in medical applications | Revotar Biopharmaceuticals AG (DE) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152291-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | SELP, SELL, SELE | RAB9A 3490/4885NPC1 1018/4885ALDH1A1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.